Further reports demonstrated that AAT reduces ENaC activity both in vitro and in vivo [155]; thus, AAT may be a relevant therapeutic option in the management of impaired MCC in chronic airways disease. The gene discussed is SERPINA1; the disease is Merkel cell skin cancer.